Anticholinergic and benzodiazepine use in dementia: a systematic review with meta-analysis of anticholinergic burden and all-cause mortality
BackgroundDementia affects an estimated 57 million people worldwide, and this number is expected to rise sharply. People living with dementia (PwD) are especially vulnerable to medication-related harm due to frailty, multimorbidity, and polypharmacy. Two important forms of potentially inappropriate prescribing (PIP) that risk more harm than benefit in PwD are anticholinergic medicines (ACMs) and…
Read original article on Frontiers in Psychiatry | New and Recent Articles →